ZUMA-1

ZUMA-1 was a clinical trial testing a new CAR T-cell therapy called axicabtagene ciloleucel for treating large B-cell lymphoma, a type of blood cancer. The therapy involves collecting a patient’s own immune cells, reprogramming them in the lab to better fight cancer, and then infusing them back into the patient. The trial showed high response rates, with many patients experiencing significant tumor reduction or remission. ZUMA-1 demonstrated that this personalized immunotherapy could be a powerful option for patients who had not responded to standard treatments. It played a key role in approving CAR T-cell therapies for certain blood cancers.